The Pharma Data

DECEMBER 16, 2020

Evotec and Bristol Myers Squibb (the successor in interest to Celgene ) initiated their long-term strategic drug discovery and development partnership in the field of targeted protein degradation in 2018 with the goal to identify novel drug targets. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.

Protein 40

Protein Containment Bioinformatics Drugs 40

pharmaphorum

SEPTEMBER 14, 2020

Here he gives us a deeper look at how genomic medicine is evolving and the barriers that are preventing it from reaching its full potential. I saw this, in particular, with the finishing of the human genome,” says Charlie. “At In reality, finishing the human genome was the first step of what is a long journey.”.

Genome 117

Genome Genomics Medicine Gene 117

XTalks

NOVEMBER 7, 2022

These tumor-derived entities are used to derive genomic and proteomic data. Detection of Genomic Alterations from cfDNA: Targeted, Non-Personalized Approaches. Detection of Genomic Alterations from cfDNA: Personalized, Targeted Assays. Optimal methods for bioinformatic analysis are still needed.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

XTalks

DECEMBER 13, 2023

This impressive growth can be attributed to Fulgent’s distinctive chemistries and advanced proprietary bioinformatics pipeline, which have been instrumental in fueling the company’s rapid advancement in recent years. Alpine Immune Sciences has recently announced an augmentation in its R&D investment. million and $38.8 million and $33.9

Genetics 111

Genetics Vaccination Vaccine DNA 111

Drug Discovery World

NOVEMBER 15, 2022

Gene-to-antibody production begins with scientists entering antibody sequences as starting material, after which bioinformatics tools filter out potentially non-viable sequences. The libraries contain only the sequences that occur in the human repertoire, rather than randomly generated sequences,” adds Dr Leproust. .

DNA 98

DNA Drugs Antibody Engineer 98

Drug Discovery World

JULY 29, 2022

Scientists from seven research institutions including the University of Oxford and the University of Edinburgh have used pioneering bioinformatic modelling to investigate the molecular interactions of the p53 protein known to give protection against cancers.

Gene 52

Gene DNA Protein Genetics 52